Litcius/Paper detail

Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review

Alessandro Mantovani, Christopher D Byrne, Giovanni Targher

2022˜The œLancet. Gastroenterology & hepatology207 citationsDOIOpen Access PDF

Topics & Concepts

MedicineFatty liverGlucagon-like peptide 1 receptorEmpagliflozinLiraglutideReceptorInternal medicinePharmacologyClinical trialNonalcoholic fatty liver diseaseSteatohepatitisEndocrinologyType 2 diabetesPeroxisomePeroxisome proliferator-activated receptor alphaDiseasePeroxisome proliferator-activated receptorSteatosisBioinformaticsLiver diseaseMineralocorticoid receptorLiver enzymeMelanocortin 4 receptorLiver Disease Diagnosis and TreatmentDiabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins